Flowonix Medical said yesterday that it won FDA approval to market the updated software used to program the company’s Prometra infusion system.
The clinician programmer software, which Flowonix plans to launch in February, includes automatic calculations and increased dosing flexibility during bridge bolusing, according to the company.
Flowonix’s programmable Prometra pump is indicated for intrathecal infusion of drug therapy, including infumorph, saline and baclofen.
“We are excited to introduce the Flowonix Maestro Software into clinics around the country, as the enhancements included in the software were driven by feedback provided directly by our customers,” president & CEO Larry Heaton said in prepared remarks.
“We are confident the combination of the Flowonix Maestro Software and the novel drug delivery mechanism of the Prometra Pump will strengthen our position in the marketplace and set the company up for long-term success in targeted drug delivery,” Heaton added.
